Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pre-Exposure Prophylaxis | 3 | 2024 | 196 | 1.540 |
Why?
|
| Contraceptive Devices, Female | 2 | 2022 | 30 | 1.450 |
Why?
|
| Anti-HIV Agents | 4 | 2023 | 1324 | 1.340 |
Why?
|
| HIV Infections | 8 | 2024 | 5097 | 1.100 |
Why?
|
| Pyrimidines | 2 | 2022 | 32 | 0.870 |
Why?
|
| Grandparents | 1 | 2022 | 6 | 0.820 |
Why?
|
| Antiviral Agents | 8 | 2017 | 111 | 0.730 |
Why?
|
| Hepatitis C, Chronic | 6 | 2015 | 26 | 0.650 |
Why?
|
| Female | 15 | 2024 | 9103 | 0.470 |
Why?
|
| Hepacivirus | 6 | 2017 | 37 | 0.440 |
Why?
|
| Humans | 17 | 2024 | 14537 | 0.400 |
Why?
|
| Hepatitis C | 2 | 2017 | 37 | 0.390 |
Why?
|
| Sofosbuvir | 5 | 2017 | 8 | 0.360 |
Why?
|
| Intimate Partner Violence | 2 | 2022 | 55 | 0.360 |
Why?
|
| Uridine Monophosphate | 3 | 2014 | 3 | 0.340 |
Why?
|
| Viral Nonstructural Proteins | 4 | 2017 | 15 | 0.320 |
Why?
|
| Carbamates | 3 | 2017 | 12 | 0.300 |
Why?
|
| Male | 10 | 2022 | 6754 | 0.300 |
Why?
|
| Liver Transplantation | 2 | 2021 | 55 | 0.290 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2017 | 4 | 0.270 |
Why?
|
| Cholestasis | 1 | 2005 | 3 | 0.260 |
Why?
|
| Graft Rejection | 1 | 2005 | 15 | 0.260 |
Why?
|
| Double-Blind Method | 3 | 2021 | 272 | 0.250 |
Why?
|
| Adult | 10 | 2024 | 5913 | 0.240 |
Why?
|
| Fluorenes | 2 | 2014 | 2 | 0.230 |
Why?
|
| Benzimidazoles | 2 | 2014 | 13 | 0.230 |
Why?
|
| Young Adult | 6 | 2024 | 2498 | 0.230 |
Why?
|
| Africa South of the Sahara | 2 | 2022 | 353 | 0.220 |
Why?
|
| Africa, Southern | 1 | 2023 | 91 | 0.220 |
Why?
|
| Focus Groups | 1 | 2024 | 196 | 0.210 |
Why?
|
| Qualitative Research | 1 | 2024 | 321 | 0.200 |
Why?
|
| Decision Making | 1 | 2022 | 53 | 0.200 |
Why?
|
| Contraceptive Agents, Female | 1 | 2022 | 47 | 0.190 |
Why?
|
| Ribavirin | 5 | 2015 | 15 | 0.190 |
Why?
|
| Breast Feeding | 1 | 2022 | 120 | 0.190 |
Why?
|
| Sexual Behavior | 1 | 2023 | 320 | 0.190 |
Why?
|
| Hepatorenal Syndrome | 1 | 2021 | 1 | 0.190 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 6 | 0.190 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 103 | 0.190 |
Why?
|
| Mothers | 1 | 2022 | 195 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 187 | 0.180 |
Why?
|
| Pregnancy | 2 | 2024 | 1862 | 0.170 |
Why?
|
| Patient Participation | 1 | 2019 | 13 | 0.170 |
Why?
|
| Adolescent | 2 | 2024 | 2985 | 0.170 |
Why?
|
| Vagina | 1 | 2020 | 91 | 0.170 |
Why?
|
| Genotype | 6 | 2017 | 442 | 0.160 |
Why?
|
| South Africa | 4 | 2024 | 7596 | 0.150 |
Why?
|
| HIV Seropositivity | 1 | 2020 | 265 | 0.140 |
Why?
|
| Macrocyclic Compounds | 1 | 2017 | 1 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2017 | 10 | 0.140 |
Why?
|
| Viral Load | 3 | 2015 | 819 | 0.130 |
Why?
|
| Middle Aged | 7 | 2021 | 3601 | 0.130 |
Why?
|
| Aged | 6 | 2017 | 1740 | 0.130 |
Why?
|
| Oligopeptides | 1 | 2015 | 16 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2021 | 889 | 0.120 |
Why?
|
| Imidazoles | 1 | 2014 | 9 | 0.110 |
Why?
|
| Liver Cirrhosis | 3 | 2021 | 28 | 0.110 |
Why?
|
| Interferon-alpha | 2 | 2015 | 15 | 0.100 |
Why?
|
| Drug Therapy, Combination | 4 | 2015 | 279 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2017 | 42 | 0.100 |
Why?
|
| HIV-1 | 1 | 2020 | 1260 | 0.100 |
Why?
|
| Drug Resistance, Viral | 3 | 2017 | 278 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2015 | 799 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2022 | 1160 | 0.070 |
Why?
|
| Anemia | 1 | 2007 | 41 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 20 | 0.060 |
Why?
|
| Protease Inhibitors | 2 | 2017 | 23 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2005 | 149 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 105 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 468 | 0.060 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2024 | 9 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 156 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2014 | 303 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2022 | 121 | 0.050 |
Why?
|
| Mental Health | 1 | 2022 | 91 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2015 | 73 | 0.050 |
Why?
|
| Albumins | 1 | 2021 | 8 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 25 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 16 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 6 | 0.050 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 17 | 0.050 |
Why?
|
| Incidence | 1 | 2022 | 685 | 0.040 |
Why?
|
| HIV | 1 | 2022 | 380 | 0.040 |
Why?
|
| Ethics, Research | 1 | 2019 | 6 | 0.040 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2019 | 24 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 34 | 0.040 |
Why?
|
| Aminoisobutyric Acids | 1 | 2017 | 1 | 0.040 |
Why?
|
| Proline | 1 | 2017 | 1 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2017 | 1 | 0.040 |
Why?
|
| Lactams, Macrocyclic | 1 | 2017 | 1 | 0.040 |
Why?
|
| Leucine | 1 | 2017 | 4 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2017 | 123 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 49 | 0.030 |
Why?
|
| Nucleotidyltransferases | 1 | 2014 | 1 | 0.030 |
Why?
|
| Pyrrolidines | 1 | 2014 | 4 | 0.030 |
Why?
|
| Valine | 1 | 2014 | 6 | 0.030 |
Why?
|
| Erythropoietin | 1 | 2007 | 8 | 0.020 |
Why?
|
| Quality of Life | 1 | 2007 | 177 | 0.020 |
Why?
|